#### Clinical N (CN)  
<table>
<tr>
<th>N Category</th>
<th>N Criteria</th>
</tr>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>NO</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>One or more ipsilateral lymph nodes, none larger than 6 cm</td>
</tr>
<tr>
<td>N2</td>
<td>Contralateral or bilateral lymph nodes, none larger than 6 cm</td>
</tr>
<tr>
<td>N3</td>
<td>Lymph node(s) larger than 6 cm</td>
</tr>
</table>  
#### Pathological N (pN)  
<table>
<tr>
<th>N Category</th>
<th>N Criteria</th>
</tr>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>pNO</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>pN1</td>
<td>Metastasis in 4 or fewer lymph nodes</td>
</tr>
<tr>
<td>pN2</td>
<td>Metastasis in more than 4 lymph nodes</td>
</tr>
</table>  
#### Definition of Distant Metastasis (M)  
<table>
<tr>
<th>M Category</th>
<th>M Criteria</th>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
</table><table>
<tr>
<th>When T is ...</th>
<th>And N is ...</th>
<th>And M is ...</th>
<th>Then the stage group is ...</th>
</tr>
<tr>
<td>TO, T1 or T2</td>
<td>NO or N1</td>
<td>M0</td>
<td>I</td>
</tr>
<tr>
<td>TO, T1 or T2</td>
<td>N2</td>
<td>MO</td>
<td>II</td>
</tr>
<tr>
<td>T3</td>
<td>NO, N1 or N2</td>
<td>M0</td>
<td>II</td>
</tr>
<tr>
<td>TO, T1, T2, T3 or T4</td>
<td>N3</td>
<td>M0</td>
<td>III</td>
</tr>
<tr>
<td>T4</td>
<td>NO, N1, N2 or N3</td>
<td>MO</td>
<td>III</td>
</tr>
<tr>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>IV</td>
</tr>
</table><table>
<tr>
<th>When T is ...</th>
<th>And N is ...</th>
<th>And M is ...</th>
<th>Then the stage group is ...</th>
</tr>
<tr>
<td>TO, T1 or T2</td>
<td>NO, N1</td>
<td>MO</td>
<td>I</td>
</tr>
<tr>
<td>TO, T1 or T2</td>
<td>N2</td>
<td>MO</td>
<td>II</td>
</tr>
<tr>
<td>T3 or T4</td>
<td>NO, N1</td>
<td>MO</td>
<td>II</td>
</tr>
<tr>
<td>T3 or T4</td>
<td>N2</td>
<td>MO</td>
<td>III</td>
</tr>
<tr>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>IV</td>
</tr>
</table>1\. Tumor location (posterior wall nasopharynx or pharyn-
geal tonsils)  
2\. Number and size of nodes  
3\. Perineural invasion  
4\. Extranodal extension gross â‰¥2 mm or microscopic  
5\. Smoking history and pack yearsNo grading system exists for HPV-mediated oropharyngeal
tumors.The histopathology of HPV-mediated p16+ oropharyngeal
cancers is characteristic and easily recognizable.  
<!-- PageBreak -->  
<!-- PageNumber="121" -->
<!-- PageHeader="10 HPV-Mediated (p16+) Oropharyngeal Cancer" -->